## **Other relevant codes** Here is the list of other relevant HCPCS codes to Q5121 in bullet format: - **Q5102**: Injection, infliximab, biosimilar, 10 mg - **Q5103**: Injection, infliximab-dyyb, biosimilar (Inflectra), 10 mg - **Q5104**: Injection, infliximab-abda, biosimilar (Renflexis), 10 mg - **Q5115**: Injection, rituximab-abbs, biosimilar (Truxima), 10 mg - **Q5118**: Injection, bevacizumab-bvzr, biosimilar (Zirabev), 10 mg - **Q5119**: Injection, rituximab-pvvr, biosimilar (Ruxience), 10 mg - **Q5122**: Injection, pegfilgrastim-apgf, biosimilar (Nyvepria), 0.5 mg - **Q5123**: Injection, rituximab-arrx, biosimilar (Riabni), 10 mg Frequently asked questions
Always consult with a healthcare professional to determine if these injections are suitable for your specific needs and health goals
On rare occasion, a patient may experience tiny bumps beneath the skin, a rash, headache, or itchy skin
Serious vaccine reactions are rare, but individuals should seek medical advice for symptoms like significant shoulder pain, signs of infection at the injection site, or anaphylaxis, which includes swelling of the face, rapid heartbeat, and trouble breathing
The subsequent Phase IIb OPTIONS trial enrolled 536 subjects over 24 weeks
